<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624334</url>
  </required_header>
  <id_info>
    <org_study_id>110933</org_study_id>
    <nct_id>NCT04624334</nct_id>
  </id_info>
  <brief_title>Non-invasive Assessment of Colonic Motility</brief_title>
  <acronym>non-CoMoti</acronym>
  <official_title>Electro-Entero-Graphy (EEnG) for Non-invasive Diagnosis of Motility Disorders of the Bowel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current diagnostic process of colonic motility disorders often takes a long time and&#xD;
      involves multiple invasive, painful and/or unnecessary diagnostic procedures. To improve this&#xD;
      diagnostic process, the potential of Electro-Entero-Graphy (EEnG) is investigated.&#xD;
&#xD;
      During the EEnG procedure, several surface electrodes are positioned (under ultrasound&#xD;
      guidance) on the abdomen so that electrical activity originating in the colon can be&#xD;
      measured. Measurements will be performed after a period of fasting (when the colon is&#xD;
      'silent') and just after a meal (when the colon is moving) in both participants suffering&#xD;
      from colonic motility disorders and healthy controls.&#xD;
&#xD;
      It is hypothesized that these measurements are an indication of colonic motility and can be&#xD;
      used as a diagnostic tool for colonic motility disorders. It is also hypothesized that this&#xD;
      EEnG procedure is not more burdensome than the Gold Standard procedures for diagnosing&#xD;
      colonic motility disorders. This will be assessed using questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Power Percent Difference</measure>
    <time_frame>During EEnG procedure</time_frame>
    <description>Relative power change when comparing pre-prandial EEnG measurements to post-prandial measurements. Power will be calculated as the mean amplitude (mV^2/Hz) in a bandwidth of 2 cycles per minute around the dominant frequency related to colonic movements (between 2-10 cycles per minute).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEnG questionnaire score</measure>
    <time_frame>Directly after EEnG procedure, which is a one time procedure the subjects in this study will undergo</time_frame>
    <description>Burden score of EEnG procedure as assessed by a self created questionnaire (in collaboration with medical doctors, a psychologist and representatives of the patients association). A mean score of 0 indicates maximum burden, a mean score of 10 means no burden at all.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gold Standard questionnaire score</measure>
    <time_frame>Directly after EEnG procedure, which is a one time procedure the subjects in this study will undergo, or directly after the gold standard procedure, which some subjects will undergo in the near future at time of inclusion</time_frame>
    <description>Total burden score of Gold Standard procedure used to diagnose motility disorder as assessed by a self created questionnaire (in collaboration with medical doctors, a psychologist and representatives of the patients association). A mean score of 0 indicates maximum burden, a mean score of 10 means no burden at all.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colon Disease</condition>
  <condition>Functional Constipation</condition>
  <condition>Electroenterography</condition>
  <condition>Slow Transit</condition>
  <condition>Hirschsprung Disease</condition>
  <arm_group>
    <arm_group_label>Children with motility disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy children</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults with motility disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy adults</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elektro-Entero-Graphy procedure</intervention_name>
    <description>Fasting, after which pre- and postprandial EEnG measurements are performed.</description>
    <arm_group_label>Adults with motility disorder</arm_group_label>
    <arm_group_label>Children with motility disorder</arm_group_label>
    <arm_group_label>Healthy adults</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EEnG Questionnaire</intervention_name>
    <description>Filling out questionnaire about EEnG procedure.</description>
    <arm_group_label>Adults with motility disorder</arm_group_label>
    <arm_group_label>Children with motility disorder</arm_group_label>
    <arm_group_label>Healthy adults</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gold Standard Questionnaire</intervention_name>
    <description>Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.</description>
    <arm_group_label>Adults with motility disorder</arm_group_label>
    <arm_group_label>Children with motility disorder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects fulfilling the in- and exclusion criteria will be included. Participants with&#xD;
        (suspected) motility disorder will be recruited mainly in the Radboudumc and with the help&#xD;
        from the Hirschsprung's patient association.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All participants:&#xD;
&#xD;
          -  Age ≤ 11 years for babies and children&#xD;
&#xD;
          -  Age ≥ 18 years for adults.&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  For babies/children:&#xD;
&#xD;
               -  suffering from surgically untreated HSCR as determined by a rectal biopsy, or&#xD;
&#xD;
               -  suspected of HSCR, for which a rectal biopsy is planned&#xD;
&#xD;
          -  For adults: Suffering from a (suspected,) surgically untreated functional colonic&#xD;
             motility disorder (such as slow-transit constipation, idiopathic/therapy resistant&#xD;
             constipation of the colon), as diagnosed previously or will be diagnosed in the near&#xD;
             future using the gold standard method.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  All participants:&#xD;
&#xD;
          -  For adults: BMI &gt; 27 kg/m2&#xD;
&#xD;
          -  For babies/children: weight for length &gt; 2.5 standard deviations of WHO Child Growth&#xD;
             Standard&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Any food intolerance&#xD;
&#xD;
          -  Presence of an intestinal stoma&#xD;
&#xD;
          -  Use of continuous tube feeding&#xD;
&#xD;
          -  Healthy controls:&#xD;
&#xD;
          -  The presence of any known gastro-intestinal conditions&#xD;
&#xD;
          -  Use of laxatives in the past two years&#xD;
&#xD;
          -  Participants with (suspected) motility disorder:&#xD;
&#xD;
          -  (Part of) colon removed&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S.M.B.I. Botden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick Rolleman, BSc</last_name>
    <phone>+316 11825254</phone>
    <email>Nick.Rolleman@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Rolleman, BSc</last_name>
      <phone>+31 6 11825254</phone>
      <email>nick.rolleman@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hirschsprung Disease</mesh_term>
    <mesh_term>Colonic Diseases</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be available to other researchers on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After publication of the results.</ipd_time_frame>
    <ipd_access_criteria>Upon reasonable request via e-mail.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

